Cathepsin cysteine protease inhibitors

A compound of the formula:

• wherein
• R1 is hydrogen, C1-6 alkyl C2-6 alkenyl, C3-8 cycloalkyl or heterocyclyl, wherein said alkyl and alkenyl groups are optionally substituted with one to six substituents independently selected from the group consisting of hydroxy, C3-6 cycloalkyl, halo and R8;
• and wherein said cycloalkyl and heterocyclyl groups are optionally substituted with one or two substituents independently selected from the group consisting of C1-6 alkyl, halo, OR6 and keto;
• R2 is hydrogen, C1-6 alkyl or C2-6 alkenyl wherein said alkyl and alkenyl groups are optionally substituted with one to six substituents independently selected from the group consisting of hydroxy, C3-6 cycloalkyl, halo and R8;
• or R1 and R2 can be taken together with the carbon atom to which they are attached to form a C3-6 cycloalkyl or heterocyclyl ring wherein said cycloalkyl and heterocyclyl rings are optionally substituted with one to two substituents independently selected from the group consisting of R6, C1-6 haloalkyl and halo;
• each R is independently selected from the group consisting of halo, and C1-2 alkyl, wherein said alkyl group is optionally substituted with one to three halo;
• or
• two R3 groups on adjacent carbons can be taken together with the carbon atoms to which they are attached to form a C3-4 cycloalkyl ring, wherein said ring is optionally substituted with one to three halo;
• R4a is aryl or heteroaryl, wherein said aryl and heteroaryl groups are optionally substituted with one to four substituents independently selected from the group consisting of halo, hydroxy, cyano, R6, OR6 and R8;
• R4b is hydrogen or C1-6 alkyl which is optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxy, cyano and O(C1-6 alkyl);
• or R4a and R4b can be taken together with the atoms to which they are attached to form a 4 to 7 membered saturated or unsaturated ring wherein said ring is optionally substituted with one to two substituents independently selected from the group consisting of R6, C1-6 haloalkyl and halo;
• R5 is hydrogen, C1-6 alkyl, C2-6 alkenyl, C1-6 haloalkyl, aryl, heteroaryl, C3-8 cycloalkyl, heterocycyl, C(O)NR6R8, C(O)R8, NR6C(O)OR7 or SOmR6, wherein said aryl, heteroaryl, cycloalkyl and heterocycyl groups are optionally substituted with one to five substituents independently selected from the group consisting of C1-6 alkyl, halo, oxo, cyano, C1-6 haloalkyl, OR6, C(O)NR6R7, C(O)OR6, C(O)R6, ═NR6, ═NCN and SO, 6′
• R6 is hydrogen or C1-6 alkyl, which is optionally substituted with one to four substituents independently selected from the group consisting of halo, hydroxy, cyano, C1-3 haloalkyl, and O(C1-6 alkyl);
• R7 is hydrogen or C1-6 alkyl. which is optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxy, cyano and O(C1-6 alkyl);
• R8 is C3-8 cycloalkyl, aryl, heteroaryl or heterocyclyl, wherein said cycloalkyl, aryl, heteroaryl and heterocyclyl groups are optionally substituted with one to four substituents independently selected from the group consisting of halo, cyano, oxo, R6, OR6, NR6R7, C3-6 cycloalkyl, aryl, heteroaryl, heterocyclyl, SOmR6 and SF5;
• m in an integer from zero to two;
• p is an integer from zero to two;
• or a pharmaceutically acceptable salt thereof.